Filtering by:
Soft Tissue SarcomaFDA Approves Tazverik (Tazemetostat) for Epithelioid Sarcoma
The US Food and Drug Administration (FDA) has approved Tazverik (tazemetostat) to treat adults and children 16 and older with epithelioid sarcoma, a rare cancer which accounts for less than 1% of all soft tissue sarcomas.
FDA Approves Vitrakvi (Larotrectinib) for Tumors With Certain Genetic Change
For the second time, the US Food and Drug Administration (FDA) has approved a drug to treat tumors with a specific genetic change regardless of the type of cancer. Vitrakvi (larotrectinib) is for adults and children with solid tumors that test positive for NTRK genes, which can help cancerous tumors grow.
Liposarcoma Survivor Shares Story to Inspire Hope
When soft tissue sarcoma survivor Apreal Cloutier first noticed a lump on the back of her thigh in late 2015, she had no idea it might be cancer.
Cancer Facts and Figures: Death Rate Down 25% Since 1991
The death rate from cancer in the US has declined steadily over the past 2 decades, according to annual statistics reporting from the American Cancer Society.
New Cancer Drug Approvals From 2016
In 2016, the FDA approved several new drug treatments for different cancer types that American Cancer Society editors believe will make a significant difference.
FDA Approves Lartruvo for Soft Tissue Sarcoma
The US Food and Drug Administration (FDA) has approved Lartruvo (olaratumab) for advanced soft tissue sarcoma.
FDA Approves Halaven (Eribulin) for Liposarcoma
The US Food and Drug Administration (FDA) has approved the chemotherapy drug Halaven (eribulin) to treat liposarcoma, a type of soft tissue sarcoma.
FDA Approves Yondelis (Trabectedin) for Advanced Soft Tissue Sarcoma
The US Food and Drug Administration (FDA) has approved the chemotherapy drug Yondelis (trabectedin) to treat 2 types of soft tissue sarcomas – liposarcoma and leiomyosarcoma – that have spread to other parts of the body and/or cannot be removed through surgery.